Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia
作者:Mark E. Layton、Jeffrey C. Kern、Timothy J. Hartingh、William D. Shipe、Izzat Raheem、Monika Kandebo、Robert P. Hayes、Sarah Huszar、Donnie Eddins、Bennett Ma、Joy Fuerst、Gordon K. Wollenberg、Jing Li、Jeff Fritzen、Georgia B. McGaughey、Jason M. Uslaner、Sean M. Smith、Paul J. Coleman、Christopher D. Cox
DOI:10.1021/acs.jmedchem.2c01521
日期:2023.1.26
novel means for its treatment. With the goal of developing PDE10A inhibitors, early optimization of a fragment hit through rational design led to a series of potent pyrimidine PDE10A inhibitors that required further improvements in physicochemical properties, off-target activities, and pharmacokinetics. Herein we describe the discovery of an isomeric pyrimidine series that addresses the liabilities seen
PDE10A 是纹状体信号传导的重要调节因子,当受到抑制时,可以使功能失调的活动正常化。鉴于精神分裂症涉及纹状体活动功能障碍,PDE10A 抑制代表了一种潜在的新治疗方法。以开发 PDE10A 抑制剂为目标,通过合理设计对片段进行早期优化,产生了一系列有效的嘧啶 PDE10A 抑制剂,需要在理化性质、脱靶活性和药代动力学方面进一步改进。在此,我们描述了异构嘧啶系列的发现,该系列解决了早期化合物的缺陷,并导致了化合物18 (MK-8189) 的发明,该化合物目前处于治疗精神分裂症的 2b 期临床开发阶段。